Ultragenyx Pharmaceutical Inc. (RARE) · Insider trading
What Ultragenyx Pharmaceutical's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$3.70M
9 insiders, 36% under a plan
Net, 12 months
−$3.70M
bought less sold
Latest filing
2026-09-15
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Kakkis Emil DDirector, President & CEO | – | $6.30M | 5 | 2026-03-02 | 658,994 |
| Horn HowardChief Financial Officer | – | $1.40M | 13 | 2026-08-03 | 96,295 |
| Parschauer Karah HerdmanEVP and Chief Legal Officer | – | $1.23M | 9 | 2026-08-03 | 92,562 |
| Harris ErikEVP & Chief Commercial Officer | – | $876,126 | 2 | 2026-03-02 | 89,515 |
| Pinion John RichardSee Remarks | – | $836,543 | 2 | 2026-03-02 | 110,026 |
| Crombez EricEVP and Chief Medical Officer | – | $574,333 | 5 | 2026-05-05 | 111,189 |
| Kassberg Thomas RichardCBO & EVP | – | $253,779 | 1 | 2025-03-03 | 265,238 |
| Suliman ShehnaazDirector | – | $144,189 | 1 | 2026-05-18 | 27,951 |
| Sanders Corazon (Corsee) D.Director | – | $140,023 | 2 | 2026-06-15 | 21,095 |
| Huizenga Theodore AlanSVP, Chief Accounting Officer | – | $105,009 | 7 | 2026-09-15 | 67,863 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Saleplan | 1,283 | 13.57 | $17,410 | 67,863 | Form 4 |
| 2026-09-03 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 161 | 13.99 | $2,252 | 69,146 | Form 4 |
| 2026-08-03 | Horn HowardChief Financial Officer | Saleplan | 4,696 | 24.92 | $117,024 | 96,295 | Form 4 |
| 2026-08-03 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Saleplan | 1,900 | 24.92 | $47,348 | 92,562 | Form 4 |
| 2026-07-01 | Horn HowardChief Financial Officer | Saleplan | 4,698 | 33.13 | $155,645 | 100,991 | Form 4 |
| 2026-06-15 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Saleplan | 1,899 | 24.62 | $46,753 | 94,462 | Form 4 |
| 2026-06-15 | Sanders Corazon (Corsee) D.Director | Sale | 2,000 | 25.05 | $50,100 | 21,095 | Form 4 |
| 2026-06-01 | Horn HowardChief Financial Officer | Saleplan | 4,653 | 23.77 | $110,602 | 105,689 | Form 4 |
| 2026-05-18 | Suliman ShehnaazDirector | Saleplan | 5,740 | 25.12 | $144,189 | 27,951 | Form 4 |
| 2026-05-05 | Crombez EricEVP and Chief Medical Officer | Sale | 344 | 24.96 | $8,586 | 111,189 | Form 4 |
| 2026-05-01 | Horn HowardChief Financial Officer | Saleplan | 4,683 | 24.90 | $116,607 | 110,342 | Form 4 |
| 2026-04-01 | Horn HowardChief Financial Officer | Saleplan | 4,683 | 20.97 | $98,203 | 80,351 | Form 4 |
| 2026-03-10 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 3,508 | 22.67 | $79,526 | 66,820 | Form 4 |
| 2026-03-06 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 6,018 | 21.40 | $128,785 | 70,328 | Form 4 |
| 2026-03-03 | Horn HowardChief Financial Officer | Saleplan | 1,635 | 22.40 | $36,624 | 85,034 | Form 4 |
| 2026-03-02 | Crombez EricEVP and Chief Medical Officer | Sale | 7,029 | 22.80 | $160,261 | 76,301 | Form 4 |
| 2026-03-02 | Horn HowardChief Financial Officer | Saleplan | 5,290 | 22.80 | $120,612 | 89,788 | Form 4 |
| 2026-03-02 | Horn HowardChief Financial Officer | Saleplan | 3,119 | 22.54 | $70,302 | 86,669 | Form 4 |
| 2026-03-02 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 1,632 | 22.80 | $37,210 | 48,670 | Form 4 |
| 2026-03-02 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 8,135 | 22.80 | $185,478 | 76,346 | Form 4 |
| 2026-03-02 | Kakkis Emil DDirector, President & CEO | Sale | 54,404 | 22.80 | $1.24M | 658,994 | Form 4 |
| 2026-03-02 | Harris ErikEVP & Chief Commercial Officer | Sale | 10,539 | 22.80 | $240,289 | 89,515 | Form 4 |
| 2026-03-02 | Pinion John RichardSee Remarks | Sale | 10,029 | 22.80 | $228,661 | 110,026 | Form 4 |
| 2026-02-02 | Horn HowardChief Financial Officer | Saleplan | 3,061 | 23.56 | $72,117 | 88,935 | Form 4 |
| 2026-01-02 | Horn HowardChief Financial Officer | Saleplan | 3,150 | 22.84 | $71,946 | 91,996 | Form 4 |
| 2025-12-29 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 85 | 34.38 | $2,922 | 50,450 | Form 4 |
| 2025-12-10 | Horn HowardChief Financial Officer | Saleplan | 3,081 | 36.38 | $112,087 | 95,146 | Form 4 |
| 2025-10-13 | Horn HowardChief Financial Officer | Sale | 7,942 | 31.51 | $250,252 | 98,227 | Form 4 |
| 2025-09-18 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 64 | 29.17 | $1,867 | 50,242 | Form 4 |
| 2025-09-12 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 2,450 | 31.17 | $76,366 | 73,271 | Form 4 |
| 2025-09-05 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 84 | 31.39 | $2,637 | 50,306 | Form 4 |
| 2025-06-20 | Sanders Corazon (Corsee) D.Director | Saleplan | 2,405 | 37.39 | $89,923 | 15,344 | Form 4 |
| 2025-05-05 | Crombez EricEVP and Chief Medical Officer | Sale | 520 | 39.24 | $20,405 | 71,530 | Form 4 |
| 2025-04-21 | Crombez EricEVP and Chief Medical Officer | Sale | 242 | 35.11 | $8,497 | 71,680 | Form 4 |
| 2025-03-06 | Horn HowardChief Financial Officer | Sale | 1,785 | 40.40 | $72,114 | 106,169 | Form 4 |
| 2025-03-03 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | 967 | 42.10 | $40,711 | 50,265 | Form 4 |
| 2025-03-03 | Harris ErikEVP & Chief Commercial Officer | Sale | 15,103 | 42.10 | $635,836 | 87,855 | Form 4 |
| 2025-03-03 | Kakkis Emil DDirector, President & CEO | Saleplan | 73,434 | 42.10 | $3.09M | 641,731 | Form 4 |
| 2025-03-03 | Pinion John RichardSee Remarks | Sale | 14,439 | 42.10 | $607,882 | 107,766 | Form 4 |
| 2025-03-03 | Crombez EricEVP and Chief Medical Officer | Sale | 8,945 | 42.10 | $376,584 | 71,922 | Form 4 |
7 more
| 2025-03-03 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 12,846 | 42.10 | $540,817 | 75,287 | Form 4 |
| 2025-03-03 | Kassberg Thomas RichardCBO & EVP | Sale | 6,028 | 42.10 | $253,779 | 265,238 | Form 4 |
| 2025-02-28 | Kakkis Emil DDirector, President & CEO | Saleplanindirect | 25,000 | 42.48 | $1.06M | 2,158,985 | Form 4 |
| 2025-02-27 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 2,230 | 42.93 | $95,734 | 55,751 | Form 4 |
| 2025-02-27 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | 760 | 42.75 | $32,490 | 54,991 | Form 4 |
| 2024-12-30 | Kakkis Emil DDirector, President & CEO | Saleplanindirect | 11,727 | 42.23 | $495,231 | 2,183,985 | Form 4 |
| 2024-12-10 | Kakkis Emil DDirector, President & CEO | Saleplanindirect | 8,273 | 50.00 | $413,650 | 2,195,712 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
44 × grant or award6 × shares withheld for tax2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-05-14 | Dunsire DeborahDirector | Grant or award A | +7,751 | – | 38,566 | Form 4 |
| 2026-05-14 | Welch Daniel GDirector | Grant or award A | +7,751 | – | 40,441 | Form 4 |
| 2026-05-14 | Narachi MichaelDirector | Grant or award A | +7,751 | – | 40,441 | Form 4 |
| 2026-05-14 | Fust Matthew KDirector | Grant or award A | +7,751 | – | 33,696 | Form 4 |
| 2026-05-14 | Suliman ShehnaazDirector | Grant or award A | +7,751 | – | 33,691 | Form 4 |
| 2026-05-14 | Sanders Corazon (Corsee) D.Director | Grant or award A | +7,751 | – | 23,095 | Form 4 |
| 2026-05-14 | Ray AmritDirector | Grant or award A | +7,751 | – | 31,116 | Form 4 |
| 2026-04-22 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Grant or award A | +20,241 | – | 68,911 | Form 4 |
| 2026-04-16 | Horn HowardChief Financial Officer | Grant or award A | +34,674 | – | 115,025 | Form 4 |
| 2026-04-16 | Crombez EricEVP and Chief Medical Officer | Grant or award A | +34,674 | – | 110,975 | Form 4 |
| 2026-04-16 | Harris ErikEVP & Chief Commercial Officer | Grant or award A | +28,895 | – | 118,410 | Form 4 |
| 2026-04-16 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Grant or award A | +28,895 | – | 95,715 | Form 4 |
| 2026-04-16 | Pinion John RichardSee Remarks | Grant or award A | +23,116 | – | 133,142 | Form 4 |
| 2026-04-16 | Huang Dennis KarlSee Remarks | Grant or award A | +23,116 | – | 147,845 | Form 4 |
| 2026-04-16 | Kakkis Emil DDirector, President & CEO | Grant or award A | +76,745 | – | 735,739 | Form 4 |
| 2026-03-02 | Huang Dennis KarlSee Remarks | Shares withheld for tax F | −999 | 23.39 | 124,729 | Form 4 |
| 2026-03-02 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Shares withheld for tax F | −148 | 23.39 | 50,302 | Form 4 |
| 2026-03-01 | Huang Dennis KarlSee Remarks | Grant or award A | +11,137 | – | 125,728 | Form 4 |
| 2026-03-01 | Crombez EricEVP and Chief Medical Officer | Grant or award A | +11,643 | – | 83,173 | Form 4 |
| 2026-03-01 | Horn HowardChief Financial Officer | Grant or award A | +6,143 | – | 95,078 | Form 4 |
| 2026-03-01 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Grant or award A | +11,137 | – | 84,408 | Form 4 |
| 2026-03-01 | Kakkis Emil DDirector, President & CEO | Grant or award A | +71,177 | – | 712,908 | Form 4 |
| 2026-03-01 | Harris ErikEVP & Chief Commercial Officer | Grant or award A | +11,643 | – | 99,498 | Form 4 |
| 2026-03-01 | Pinion John RichardSee Remarks | Grant or award A | +11,137 | – | 119,565 | Form 4 |
| 2025-05-15 | Ray AmritDirector | Grant or award A | +5,740 | – | 23,365 | Form 4 |
| 2025-05-15 | Dunsire DeborahDirector | Grant or award A | +5,740 | – | 30,815 | Form 4 |
| 2025-05-15 | Fust Matthew KDirector | Grant or award A | +5,740 | – | 25,945 | Form 4 |
| 2025-05-15 | Narachi MichaelDirector | Grant or award A | +5,740 | – | 32,690 | Form 4 |
| 2025-05-15 | Sanders Corazon (Corsee) D.Director | Grant or award A | +5,740 | – | 17,749 | Form 4 |
| 2025-05-15 | Welch Daniel GDirector | Grant or award A | +5,740 | – | 32,690 | Form 4 |
| 2025-05-15 | Suliman ShehnaazDirector | Grant or award A | +5,740 | – | 25,940 | Form 4 |
| 2025-03-03 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Shares withheld for tax F | −141 | 42.92 | 50,124 | Form 4 |
| 2025-03-03 | Huang Dennis KarlSee Remarks | Shares withheld for tax F | −1,348 | 42.92 | 114,591 | Form 4 |
| 2025-03-03 | Pinion John RichardSee Remarks | Shares withheld for tax F | −31 | 42.92 | 108,428 | Form 4 |
| 2025-03-03 | Kassberg Thomas RichardCBO & EVP | Shares withheld for tax F | −508 | 42.92 | 264,730 | Form 4 |
| 2025-03-01 | Horn HowardChief Financial Officer | Grant or award A | +15,653 | – | 107,954 | Form 4 |
| 2025-03-01 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Grant or award A | +9,392 | – | 51,232 | Form 4 |
| 2025-03-01 | Huang Dennis KarlSee Remarks | Grant or award A | +14,494 | – | 97,496 | Form 4 |
| 2025-03-01 | Huang Dennis KarlSee Remarks | Grant or award A | +18,443 | – | 115,939 | Form 4 |
| 2025-03-01 | Harris ErikEVP & Chief Commercial Officer | Grant or award A | +16,813 | – | 83,976 | Form 4 |
| 2025-03-01 | Harris ErikEVP & Chief Commercial Officer | Grant or award A | +18,443 | – | 102,419 | Form 4 |
| 2025-03-01 | Kakkis Emil DDirector, President & CEO | Grant or award A | +43,268 | – | 607,873 | Form 4 |
| 2025-03-01 | Kakkis Emil DDirector, President & CEO | Grant or award A | +107,292 | – | 715,165 | Form 4 |
| 2025-03-01 | Pinion John RichardSee Remarks | Grant or award A | +14,494 | – | 103,762 | Form 4 |
| 2025-03-01 | Pinion John RichardSee Remarks | Grant or award A | +18,443 | – | 122,205 | Form 4 |
| 2025-03-01 | Crombez EricEVP and Chief Medical Officer | Grant or award A | +16,813 | – | 65,244 | Form 4 |
| 2025-03-01 | Crombez EricEVP and Chief Medical Officer | Grant or award A | +14,971 | – | 80,215 | Form 4 |
| 2025-03-01 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Grant or award A | +18,443 | – | 88,133 | Form 4 |
| 2025-03-01 | Kassberg Thomas RichardCBO & EVP | Grant or award A | +18,443 | – | 271,266 | Form 4 |
| 2025-03-01 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Grant or award A | +14,494 | – | 69,690 | Form 4 |
| 2024-12-10 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Gift G | −648 | – | 41,840 | Form 4 |
| 2024-12-09 | Kakkis Emil DDirector, President & CEO | Gift G | −20,000 | – | 2,203,985 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.